Selected article for: "lmwh molecular weight heparin and low lmwh molecular weight heparin heparin"
Author: Buijsers, Baranca; Yanginlar, Cansu; Maciej-Hulme, Marissa L.; de Mast, Quirijn; van der Vlag, Johan
Title: Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
  • Cord-id: 1unb0z79
  • Document date: 2020_8_25
    • ID: 1unb0z79
    Snippet: Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanas
    Document: Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other inflammatory diseases.

    Search related documents:
    Co phrase search for related documents
    • acute aki kidney injury and administration mechanical ventilation: 1
    • acute aki kidney injury and lmwh weight heparin: 1, 2
    • acute aki kidney injury and local inflammation: 1, 2, 3
    • acute aki kidney injury and low molecular: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and administration mechanical ventilation: 1, 2, 3
    • acute ards respiratory distress syndrome and lmwh prophylactic dose: 1
    • acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and administration mechanical ventilation: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute sars cov respiratory syndrome coronavirus and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immune response and local inflammation: 1, 2, 3, 4
    • lmwh dalteparin and low molecular: 1, 2, 3
    • lmwh prophylactic dose and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • lmwh weight heparin and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25